BioCentury
ARTICLE | Company News

Basilea, Department of Health and Human Services infectious news

April 25, 2016 7:00 AM UTC

HHS’s Biomedical Advanced Research and Development Authority awarded Basilea a four-and-a-half-year contract worth up to $100 million to support Phase III trials of the company’s ceftobiprole medocaril. Basilea markets the broad-spectrum cephalosporin antibiotic in Europe as Zevtera.

Over an initial 18-month period, Basilea will receive about $20 million to work towards gaining SPAs from FDA for three Phase III trials the company plans to start by early 2017. The studies would be designed to support NDAs for ceftobiprole to treat Staphylococcus aureus bacteremia, acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP). BARDA may exercise additional options over the subsequent three years. ...